The combination of irinotecan plus carboplatin has antitumour activity in non-small-cell lung cancer (NSCLC)

By  

Inpharma, Vol. 1, Iss. 1473, 2005-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Gefitinib is an effective treatment for patients with non-small-cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor

By  

Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Activity of carboplatin in patients with advanced non-small cell lung cancer pre-treated with a non-platinum combination

By Esteban-Gonzalez Emilio   Fernández Yolanda   Villanueva Noemí   Fra Joaquin   Muñiz Isabel   Palacio Isabel   Vieitez Jose   Uña Esther   Mareque Beatriz   Lacave Angel  

Investigational New Drugs, Vol. 23, Iss. 6, 2005-12 ,pp. : 597-601

Springer Publishing Company

Access to resources Recommend Favorite

The Chinese non-small-cell lung cancer (NSCLC) drug market is expected to more than double by 2013

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 579, 2009-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data

By Nyberg Fredrik   Barratt Bryan J   Mushiroda Taisei   Takahashi Atsushi   Jawaid Ansar   Hada Shuji   Umemura Takaaki   Fukuoka Masahiro   Nakata Koichiro   Ohe Yuichiro   Kato Harubumi   Kudoh Shoji   March Ruth   Nakamura Yusuke   Kamatani Naoyuki  

Pharmacogenomics, Vol. 12, Iss. 7, 2011-07 ,pp. : 965-975

Future Medicine

Access to resources Recommend Favorite